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Objectives: To investigate if urban Africans displayed
lower levels of atheroprotective high-density lipoprotein
cholesterol (HDLC) when presenting with
communicable versus non-communicable forms of
heart disease (HD) as both acute infection and chronic
inflammation reduce HDLC levels.
Design: Hospital registry of 5328 de novo cases of
HD over a 3-year period.
Setting: Cardiology Unit, Baragwanath Hospital in
Soweto, South Africa.
Participants: A total of 1199 patients of African
descent (59% women; 57.0±13.4 years) had fasting
blood lipid levels (total cholesterol (TC), triglyceride,
HDLC and low-density lipoprotein cholesterol (LDLC))
documented on admission. Serum inflammatory
marker C reactive protein (CRP) was measured in a
subset of 367 patients (31% of cases).
Main outcome measures: Lipid profiles were
compared according to prespecified classification of
non-communicable (eg, hypertensive HD) versus
communicable (eg, rheumatic HD) HD. Low HDLC was
defined as <1.0 mmol/L for men and <1.2 mmol/L for
women, according to applicable South African Clinical
Guidelines.
Results: Overall 694 (58%) of those presenting
with HD had low HDLC levels; 344 of 678 (51%)
and 350 of 521 (67%) for non-communicable and
communicable, respectively (p<0.001). Comparatively,
overall prevalence of high TC was 32% and high LDLC
was 37%. On an adjusted basis, those with non-
communicable HD were more likely to record a low
HDLC relative to non-communicable presentations
(odds ratio (OR) 1.91, 95% CI 1.42 to 2.57; p<0.001).
There was a strong relationship between low HDLC and
higher levels of CRP, but only in women.
Conclusions: Despite largely favourable lipid profiles,
there are clear differences according to aetiology of
underlying HD in urban Africans, with younger patients
with communicable HD having particularly low levels of
HDLC. Appropriate prospective evidence is needed to
determine if persistent low levels of HDLC expose
patients to increased, long-term risk of atherosclerotic
forms of HD. The women-only inverse association
between HDLC and CRP warrants further investigation.
INTRODUCTION
Heart diseases (HDs) with infectious aeti-
ology have long been the principal forms of
cardiovascular disease (CVD) in sub-Saharan
Africa. However, epidemiological transition
has seen increased prevalence of non-
communicable forms of HD in these popula-
tions.1 This phenomenon is largely driven by
complex, population-wide changes in demo-
graphic, social and economic status, with
associated changes in lifestyle habits.2–4
Indicative of the tension between ‘old’ and
Strengths and limitations of this study
▪ We report a high prevalence of low high-density
lipoprotein cholesterol (HDLC) in de novo pre-
sentations of both communicable heart disease
and non-communicable heart disease, with a
greater prevalence in those with communicable
heart disease.
▪ The study cohort is clinically very well defined;
however the lipid data were obtained according
to clinical presentation, which may impose sys-
tematic bias to the results.
▪ This hospital registry study has provided prelim-
inary data that would support prospective investi-
gation of longer-term dyslipidaemia patterns and
their impact on heart disease incidence, both in
South Africa and in other low-and-middle-
income countries where the epidemiologic tran-
sition is currently underway.
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‘new’ forms of HD, the incidence of communicable
heart disease (CD) is sustained by the devastating epi-
demics of HIV/AIDS, tuberculosis (TB), rheumatic
heart disease (RHD) and parasitic infections with
cardiac involvement,5–7 while in parallel, the prevalence
of risk factors for non-communicable heart disease
(NCD) increases.8
Low serum levels of high-density lipoprotein choles-
terol (HDLC) are consistently and independently asso-
ciated with increased risk of atherosclerotic forms of
CVD.9 10 However, it remains uncertain whether low
HDLC is causal or just a cardiovascular risk marker.11 If
we are to extrapolate from studies in Western and Asian
populations,12–14 isolated low HDLC is associated with
increased risk for CVD in the long-term. There are
several causes of low HDLC levels, including overweight,
obesity, tobacco smoking and insulin resistance/type 2
diabetes mellitus, indicative of the important role lifestyle
factors have in mediating HDLC levels.9 Additionally, low
HDLC is a striking consequence of abnormal lipid metab-
olism in infection and inﬂammation.15 Although it has
been shown that those of African descent largely show a
favourable lipid proﬁle characterised by high HDLC
levels,16 it is unlikely that they can remain atheroprotec-
tive during an infected state.15 Indeed, in this setting, it is
probable that increasing prevalence of modiﬁable/life-
style risk factors contribute to a more advanced presenta-
tion in those with CD.8 We have previously reported that
in the geographically compact townships that comprise
Soweto in South Africa, ‘old’ and ‘new’ forms of HD are
simultaneously present.8 While this tension exists, we
have a unique opportunity to explore lipid proﬁles in
patients presenting with non-communicable versus com-
municable forms of HD.
STUDY HYPOTHESES
Having shown important ethnic differences in the lipid
proﬁles of patients of African descent presenting with
HD in the urban African enclave of Soweto,16 we
hypothesised that independent of age and sex, urban
Africans presenting with CD will demonstrate patterns of
dyslipidaemia associated with infection/inﬂammation,
particularly suboptimal levels of HDLC, versus NCD.
METHODS
Study setting and design
As described in detail previously8 17 the 3500 bed Chris
Hani Baragwanath Hospital (case load of >125 000 inpati-
ents per annum) services the tertiary care needs of Soweto
(population of 1.1 million) and surrounding communi-
ties. All suspected cardiac presentations are referred to the
hospital’s Cardiology Unit for advanced diagnostic testing
and gold-standard treatments. A prospective clinical regis-
try of all de novo presentations of the same was established
in 2006 as part of the Heart of Soweto Study and repre-
sents sub-Saharan Africa’s largest and most detailed study
of advanced forms of HD to date.17
Participants
The ‘Heart of Soweto’ cohort of de novo case presenta-
tions comprised of 5328 patients. Of these, 2185 patients
(40%) had a documented fasting lipid proﬁle (serum
total cholesterol (TC) level, triglyceride (TG), HDLC
and calculated low-density lipoprotein cholesterol
(LDLC)18 undertaken at Baragwanath Hospital on-site
pathology). None of the patients were on lipid lowering
agents at the time of presentation, as this medication
can only be prescribed at the tertiary institution.
However, some of the patients had been placed on anti-
hypertensive medication prior to their ﬁrst assessment at
the Cardiac Clinic at Baragwanath Hospital. Moreover,
only a small number of patients (39 cases) had been pre-
scribed antiretroviral therapy (ART) on presentation. All
patients provided informed consent.
Study data
A complete list of study data captured by the registry,
comprising basic sociodemographic (including self-
reported ethnicity, years of education and determining
if the patient was born in Soweto) and advanced clinical
proﬁling, has been described previously.8 17 The registry
captured all advanced clinical investigative procedures
(eg, coronary angiography, which was undertaken in all
people diagnosed with coronary artery disease (CAD)).
Echocardiography (performed on all patients) criteria
used in the study have been described in detail
previously.8 17
Case classifications
Adjudication and classiﬁcation of communicable and
non-communicable presentations of HD in this cohort
have been previously described.8 After exclusion of
those with uncomplicated hypertension (ie, without evi-
dence of cardiac dysfunction, n=380) or other non-
modiﬁable aetiologies (eg, congenital disorders), 1199
patients of African descent (22% of the total ‘Heart of
Soweto’ cohort) were included in this analysis.
Contributory diagnoses for NCD were predominantly
hypertensive heart failure (HT-HF) and CAD (without
HIV). CD was predominantly classiﬁed as HIV-dilated
cardiomyopathy (HIV-DCMO), HIV-pulmonary hyper-
tension, TB pericardial disease and pericarditis due to
other infections.
Risk factor definition
Optimum lipid levels and treatment goals with estab-
lished CVD were deﬁned according to international
guidelines9 adopted by the Lipid and Atherosclerosis
Society of South Africa and the South African Heart
Association—high TC: >4.5 mmol/L, high TGs:
>1.7 mmol/L, high LDLC: >2.5 mmol/L and low HDLC:
<1.0 for men and <1.2 mmol/L for women.19 Other risk
factors were measured on a clinical basis, as previously
described.17 Anthropometric measurements were avail-
able for calculation of body mass index (BMI, kg/m2) in
854 (71%) cases, the low reporting rate restricted to









pen: first published as 10.1136/bmjopen-2014-005069 on 14 July 2014. Downloaded from 
ambulatory patients. Obesity was deﬁned as BMI
≥30 kg/m2. Serum C reactive protein (CRP) was mea-
sured in a subset of 367 patients (31% of all cases) if
clinically indicated (eg, suspected infection). Patients
were stratiﬁed into clinically relevant CRP categories,20
as deﬁned by Dhingra et al.21 Patients with a CRP of
1 mg/L (n=19) were used as reference group and com-
pared with medium (1.1–3.0 mg/L, n=26), high (3.1–
10.0 mg/L, n=83) and very high (>10.0 mg/L, n=239)
CRP categories.
Statistical analyses
Normally distributed continuous data are presented as
the mean±SD and non-Gaussian distributed variables
as the median (IQR). Categorical data are presented as
sample number and percentages. For group compari-
sons, we initially used χ2 analysis with calculation of odds
ratios (ORs) with 95% CIs presented were appropriate
for discrete variables, and independent t tests for nor-
mally distributed continuous variables and
Mann-Whitney U test for non-parametric continuous
variables. Multiple logistic regression analyses (entry
model) were used to derive age and sex adjusted ORs
(and BMI in some analyses, as described) for the risk of
presenting with clinically relevant variables (primarily
dyslipidaemia proﬁles), according to CD HD relative to
NCD diagnosis. Signiﬁcance was accepted at the two-
sided level of p<0.05.
RESULTS
Clinical and demographic profile
Table 1 shows the sociodemographic and clinical proﬁle
of this cohort according to cardiac aetiology. Those pre-
senting with NCD (n=678, 56.5% of cohort) were older
and had higher BMI and mean systolic blood pressure
(SBP) and diastolic blood pressure (DBP) than those
with CD (n=521, 43.5%; all comparisons p<0.001).
Overall, 76 (6%) were conﬁrmed HIV positive: 15 (2%)
and 61 (12%) patients were conﬁrmed HIV positive in
NCD and CD groups, respectively (p<0.001). Apart from
higher BMIs in women (30.6±6.9 vs 26.7±5.5 kg/m2 in
men, p<0.001) there were no signiﬁcant differences
between sexes with respect to other clinical parameters.
To this, the prevalence of obesity in women was 50% as
compared with men (26%), p<0.001.
Aetiology of HD (primary diagnosis)
Overall, the most prevalent primary diagnoses were
HT-HF (n=461, 38%), DCMO (n=178, 15%) and CAD
(n=157, 12%). In those classiﬁed as NCD, HT-HF was
the main primary diagnosis (n=461, 68%), along with
CAD (without concurrent HIV infection; n=157, 23%).
DCMO (n=178, 34%), right HF (n=92, 18%) and right
HD (n=63, 12%) and other forms of primary valve
disease (n=71, 14%), were the most common diagnoses
in those classiﬁed with communicable forms of HD.
Lipid profiles
Those with CD have signiﬁcantly lower TC, LDLC and
HDLC compared with patients with NCD (table 1 and
ﬁgure 1, p<0.001 for all comparisons). Overall, women
had signiﬁcantly higher TC (4.2±1.3 vs 3.8±1.2 mmol/L,
p<0.001), LDLC (2.4±1.0 vs 2.2±1.0 mmol/L, p<0.01)
and HDLC compared with men (1.2±0.5 vs 1.0
±0.5 mmol/L, p<0.001). This gender difference did not
extend to TGs (1.1(0.4–1.8) vs 1.1(0.4–1.8) mmol/L,
p=0.7) nor TC : HDLC ratio (4.2±3.1 vs 4.3±2.7 mmol/L,
p=0.6). Lipid ratios were calculated and compared
(table 1). There were no signiﬁcant differences between
aetiology groups for either TC : HDL or TG : HDL
groups. However LDL : HDL ratios were signiﬁcantly
higher in the communicable group.
Levels of TC (ﬁgure 1A), HDLC (ﬁgure 1B) and
LDLC (ﬁgure 1C) were signiﬁcantly higher in women
with NCD (ﬁgure 1). However, in those diagnosed with
CD, small, but signiﬁcant, differences were observed
only for TC and HDLC, not LDL (ﬁgure 1). Overall,
prevalence of dyslipidaemia varied from 18% of patients
with high TGs to 58% with low HDLC (table 1 and
ﬁgure 2). Consistent with the decrease observed with
the actual levels, prevalence of high TC and high LDLC
was increased in those with NCD aetiologies while low
HDLC levels prevalence was higher in those with CD
(table 1 and ﬁgure 2). There were no patients with TG
levels >4.5 mmol/L (range 0.1–3.8 mmol/L) which
makes use of the Friedewald equation suitable for this
cohort.18
Table 2 shows independent associations between rele-
vant socioeconomic, demographic and clinical variables
and CD aetiology, relative to those presenting with NCD.
The effect of HD aetiology on low HDLC dyslipidaemia
was strong and consistent: adjusting for age, sex and
BMI of patients, those with forms of CD were signiﬁ-
cantly more likely to record a low HDLC relative to
those presenting with NCD (table 2, p<0.001) and less
likely to record high TC and LDLC (table 2). Patients
with CD were less likely to record high TG levels (OR
0.65, 95% CI 0.51 to 0.84, p<0.05) compared to those
with NCD.
CRP subset analysis
Overall, there was no signiﬁcant difference in CRP levels
between aetiology groups (table 1). The proportion of
conﬁrmed HIV cases in this CRP subset analysis was 7%
(n=27). Of those, 23 were in the very high-risk category.
There was also no association between CRP-derived risk
categories and high TC, LDLC or TGs (data not shown).
However, the risk of having low HDLC increased with
increasing CRP levels. In age and sex-adjusted analyses,
those with medium risk (OR 2.73, 95% CI 0.68 to 10.89,
p=0.16), high risk (OR 4.98, 95% CI 1.46 to 17.00,
p=0.01) and very high risk (OR 6.37, 95% CI 1.97
to 20.57, p<0.01) CRP levels were signiﬁcantly more
likely to record a low HDLC relative to those in the low
risk CRP group. In addition, when stratiﬁed by sex, a
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strong, positive association remained in women but was
no longer apparent in men (ﬁgure 3). In women, the
pattern was signiﬁcant across all CRP risk categories:
compared to low risk, those with medium risk (OR 12.1,
95% CI 1.21 to 120, p=0.03), high risk (OR 14.4, 95% CI
1.64 to 126, p=0.02) and very high risk (OR 23.5, 95%
CI 2.81 to 197, p=0.004) CRP levels were all more likely
to record a low HDLC. Moreover, the association was
not weakened by addition of BMI into the model (BMI
and CRP measurements available in only 230 cases) in
overall and women-only (n=133) models: those with
medium risk (OR 20.5, 95% CI 1.72 to 246, p=0.02),
high risk (OR 10.6, 95% CI 1.14 to 98.8, p=0.04) and
very high risk (OR 21.0, 95% CI 2.38 to 185, p<0.01)
CRP levels were all more likely to record a low HDLC.
DISCUSSION
We report signiﬁcant decreases in lipid levels (TC,
HDLC and LDLC) and age and BMI according to non-
communicable and communicable manifestations of de
novo HD in urban Africans, patterns that were observed
in both sexes. The high prevalence of low HDLC in
more than half of all cases, but much higher in those
with CD, is most striking. In addition, it appears that
gender is an effect modiﬁer in the relationship between
CRP and low HDLC in this cohort, but, importantly, the
relationship remains even after adjustment for the sig-
niﬁcant confounder of adiposity.
While traditionally uncommon,22 dyslipidaemia, in
particular low HDLC, is becoming more prevalent in
sub-Saharan Africa.23 24 The low lipid levels present in
the majority of cases with CD reﬂect the dramatic
changes to lipid metabolism observed in infection and is
therefore, anticipated. We acknowledge that atherogenic
LDLC is also low in this setting and that low HDLC may
not be indicative of particularly increased disease risk, at
least in the short-term. However, we still deem this as
highly clinically relevant given that even isolated low
HDLC is associated with a higher risk of atherosclerotic
forms of HD, a ﬁnding that has been seen in diverse
populations.12–14 Interestingly TG levels were not signiﬁ-
cantly increased in those with communicable forms of
HD, despite evidence that it can increase as part of
the infectious/inﬂammatory metabolic milieu.15
Additionally, we speculate that the higher lipid levels in
women may be the result of much higher rates of
obesity (50% compared with 26% in men) as the driver






n=521 (43%) p Value
Demographic profile
Mean age (years) 58.3±14.0 60.1±13.1 55.9±14.9 <0.001
Women 701 (59%) 403 (59%) 298 (57%) 0.44
<6 years formal education 582 (49%) 335 (49%) 247 (47%) 0.52
Soweto origin 562 (47%) 327 (48%) 235 (45%) 0.29
Clinical presentation
Total cholesterol (mmol/L) 4.0±1.4 4.3±1.3 3.7±1.2 <0.001
HDLC (mmol/L) 1.1±0.5 1.2±0.5 1.0±0.5 <0.001
Median triglycerides (mmol/L)* 1.1 (0.8, 1.5) 1.1 (0.8,1.6) 1.0 (0.7, 1.3) <0.001
LDLC (mmol/L) 2.4±1.0 2.5±1.0 2.2±0.9 <0.001
TC : HDLC ratio 4.3±3.0 4.2±3.1 4.4±2.7 0.27
LDL : HDLC ratio 2.5±1.1 2.5±1.0 2.7±1.1 0.36
TG : HDLC ratio* 1.1 (0.7, 1.7) 1.0 (0.7, 1.7) 1.1 (0.7, 1.8) 0.12
Median serum CRP (mg/L)* 19 (7.0, 45.0) 16.8 (6.6,41.5) 20.5 (7.8, 55.9) 0.25
Systolic BP (mm Hg) 135±29 143±29 126±26 <0.001
Diastolic BP (mm Hg) 78±16 80±16 74±16 <0.001
BMI (kg/m2) 29.0±6.7 30.3±6.7 27.2±6.2 <0.001
Prevalence of dyslipidaemia (n, %)
High total cholesterol (>5 mmol/L) 378 (32%) 266 (39%) 112 (22%) <0.001
Low HDLC (<1 in men and <1.2 mmol/L in women) 694 (58%) 344 (51%) 350 (67%) <0.001
High LDLC (>2.5 mmol/L) 446 (37%) 291 (43%) 155 (30%) <0.001
High triglycerides (>1.7 mmol/L) 215 (18%) 143 (21%) 72 (14%) 0.001
Prevalence of other risk factors (n, %)
Obese (BMI >30 kg/m2) 344 (40%) 237 (48%) 107 (30%) <0.001
Type 2 diabetes 98 (8%) 71 (11%) 27 (5%) <0.001
Past or current smoker 566 (47%) 321(47%) 245 (47%) 0.95
Family history of CVD 466 (39%) 286 (42%) 180 (35%) 0.01
Confirmed HIV-positive cases 76 (6%) 15 (2%) 61 (12%) <0.001
*Median (IQR) values presented, differences tested by Mann-Whitney U test.
BMI, body mass index (available in 854 cases); BP, blood pressure; CRP, C reactive protein (available in 367 cases); CVD, cardiovascular
disease; HDLC, high-density lipoprotein cholesterol; LDLC, low-density lipoprotein cholesterol; TG, triglycerides.
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of elevated TC, which has been suggested by authors of
a worldwide systematic analysis on high TC.25
Our interest in this phenomenon predominantly
relates to the longer-term effects of low HDLC, espe-
cially when observed together with the ampliﬁed vascu-
lar risk associated with chronic infection.15 In Africa,
where acute coronary syndromes are seen in a relatively
young population,26 we predict the very high rates of
myriads of communicable diseases27 28 will result in
more complex cases, with potentially poorer outcomes
in the long-term, given the critical role of HDLC in both
innate and adaptive immunity.15 While many infectious
diseases (bacterial and viral) have contributed to the
underlying pathology of HD reported here,5 dyslipidae-
mia associated with HIV infection has been particularly
well studied. HIV-related low HDLC is likely a conse-
quence of both the viral infection and an adverse effect
of some antiretroviral treatment regimens,28–31 however
only 39 patients of the 76 (51%) conﬁrmed HIV positive
were on ART at the time of presentation, representing
3% of the entire subset sample, which possibly dilutes
this effect.
Our CRP subset analysis found associations between
low HDLC and the pro-inﬂammatory marker CRP in
patients with newly diagnosed HD in a sex disparate
manner, with a much stronger positive association in
women. Median CRP levels were also very high across all
categories of HD aetiology, and are much higher than
previous reports in early analyses of large cohorts20 as
well as South African studies,32 but reﬂect the clinical
requirements at presentation. These high levels may also
be the result of ‘multimorbidity’ observed in the cohort,
given the prevalence of infectious disease (such as HIV/
AIDS) as well as other lifestyle factors that can also inﬂu-
ence CRP levels;33 all of which may have contributed to
Figure 1 Sex specific lipid profiles according to heart
disease aetiology. Lipid values are shown as mean±SE.
p Values indicate between-sex comparisons per aetiology
group (t test), **p<0.01; *p<0.05. NCD, non-communicable
heart disease; CD, communicable heart disease; TC, total
cholesterol; HDL, high-density lipoprotein; LDL, low-density
lipoprotein. Y-axis dotted lines show thresholds for high TC
and LDL or low HDL (sex specific values).
Figure 2 Prevalence of low high-density lipoprotein
cholesterol according to heart disease aetiology. NCD,
non-communicable heart disease; CD, communicable heart
disease. High total cholesterol (TC) >4.5 mmol/L; Low
high-density lipoprotein cholesterol (HDLC) (<1.0 mmol/L in
men, <1.2 mmol/L in women). High low-density lipoprotein
cholesterol (LDLC) >2.5 mmol/L; High triglycerides (TGs)
>1.7 mmol/L.
Table 2 Independent correlates of communicable heart
disease, relative to non-communicable heart disease.
Communicable disease
OR 95% CI
Women 0.91 0.72 to 1.15
Age 0.98 0.97 to 0.99**
Obesity 0.50 0.37 to 0.68***
<6 years formal education 1.11 0.88 to 1.42
Soweto origin 0.98 0.77 to 1.24
Body mass index adjusted analysis
High TC 0.52 0.37 to 0.71***
High LDLC 0.56 0.41 to 0.76***
Low HDLC 1.91 1.42 to 2.57***
High TG 0.65 0.51 to 0.84*
Obesity BMI >30 kg/m2; High total cholesterol (TC) >4.5 mmol/L;
High low-density lipoprotein (LDLC) >2.5 mmol/L; Low
high-density lipoprotein (HDLC) (<1.0 mmol/L in men, <1.2 mmol/L
in women). Age and sex-adjusted analysis: *p<0.05; **p<0.01;
***p<0.001.
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the high levels observed. Inﬂammatory stress may be
having a more adverse effect on HDLC in women com-
pared to men as a result of many causes. The prognostic
value of stratifying CVD risk, even at very high CRP
(>10 mg/L) levels, has been demonstrated in a very large
cohort of women,20 and there are reports of elevated
CRP in women of African descent.34 We also report
women as having a signiﬁcantly higher BMI; obesity itself
can induce a low-grade inﬂammatory response, however
the association between low HDLC and CRP in women
remained even after adjusting for BMI. While we have
assumed that the exaggerated drop in HDLC in women
with acute forms of CD is a consequence rather than a
cause of infection, treatment of atherogenic dyslipidae-
mia and inﬂammatory markers in women are of particu-
lar clinical relevance in a setting where obesity and its
antecedent behaviours are increasing.
These results underscore the need to consider multi-
factorial CVD risk burden that recognises that
co-occurrence of infectious and non-communicable
disease produces signiﬁcant and complex health dispar-
ities. Certainly, the clinical strategies to protect the heart
and vessels in acute infection differ from those required
in chronic infection and it is unlikely that lipid measure-
ments will form a cornerstone of treatment in such cases.
However, it is important to recognise the beneﬁts of early
detection and treatment of dyslipidaemia in order to
mitigate any double effect of infectious and ‘lifestyle’ HD
risk factors in the longer term. While the epidemiological
evidence is clear, the precise mechanism by which HDLC
decreases atherosclerotic CVD risk remains unclear;11
indeed, efforts to develop pharmacological modalities to
speciﬁcally increase HDLC levels to reduce cardiovascu-
lar risk, continues to be problematic10 and we acknow-
ledge that addressing the low HDLC observed in this
cohort, in isolation, without commensurate improve-
ments in HDLC functionality, will prove a difﬁcult task.
This does not, however, preclude the use of other thera-
peutic interventions that address the greater, more
complex risk presentation of cases that fall in the ‘cross-
over’ between communicable and non-communicable
diseases. For example, the polypill, which includes
lipid-lowering medications, has been proposed as a viable
treatment option in secondary prevention, given its rela-
tive ease of use and efﬁcacy in low-income settings.35
More so, evidence that statins also exert immunomodula-
tory effects, along with suggestions they may prove useful
in the treatment and prevention of infections,36 indicate
they may have important, multifaceted clinical implica-
tions in populations such as Soweto, especially given the
substantial dyslipidaemic risk associated with highly
prevalent HIV infection and ART. Attempts to address
prevention, management, cure and control of non-
communicable and communicable forms of HD as
entirely separate entities are likely to prove insufﬁcient.
This holds true on a per-patient basis as well as for any
population-wide, public health approach.
There are a number of limitations that require consid-
eration. Clinical data (other than routine echocardiog-
raphy and 12-lead ECG) were obtained according to
presentation. This study was not speciﬁcally designed to
comprehensively delineate between speciﬁc forms of
HD (resulting in variable clinical data) although this is
part of clinical investigation at Baragwanath Hospital;
although it should be noted HIV status is not routinely
determined. The arbitrary selection of disease states into
the communicable versus non-communicable groups
(eg, primary valve disease) may be questioned; hence
our further delineation of clearly identiﬁable cases of
acute inﬂammation/infection at the point of admission.
However, we would emphasise that classiﬁcation was pro-
spectively applied, the groupings are consistent with our
previous reports that describe in detail the rigorous clin-
ical criteria employed in proﬁling the ‘Heart of Soweto’
cohort, and expected gradients in lipid levels were subse-
quently found. Systematic bias needs to be carefully con-
sidered before attributing broad patterns in lipid
proﬁles, as those with suspected atherosclerotic disease
were more likely to have had lipid levels measured,
reﬂecting the low number of those presenting an acute
infectious form of HD (eg, patients with pericarditis).
Adiposity, a major confounder of dyslipidaemia and HD,
was recorded in 71% of the cohort. However, its inclu-
sion in the regression analyses did not alter the signiﬁ-
cance of the associations. Central obesity measurements
(eg, waist-to-hip ratio) may have offered greater delinea-
tion of CVD risk but data were not available. CRP was
measured in just under one third of cases and related
data require careful interpretation. Finally, owing to the
cross-sectional design of this study we were not able to
investigate the possible effect of the magnitude and
timing of the contributing infection on lipid levels,
beyond the data collected at admission. Given the transi-
ent, dynamic processes of lipid metabolism over the
course of acute and chronic diseases, only longitudinal
studies of lipid levels and subsequent outcomes can fully
elucidate the clinical importance of our ﬁndings.
Figure 3 Risk of low high-density lipoprotein cholesterol
according to C reactive protein risk group, relative to low-risk
C reactive protein group (n=367). Age-adjusted analysis.
CRP=C reactive protein. **p<0.01; *p<0.05 relative to low
CRP group. For CIs, please refer to the Results section.
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CONCLUSIONS
We have shown that despite largely favourable lipid pro-
ﬁles, there are clear differences according to underlying
aetiology of HD in urban Africans however, overall low
HDLC was the most prevalent metabolic abnormality
observed in this cohort. Younger Africans with CD have
particularly low levels of HDLC that, if maintained in
the longer term, may leave them at increased risk of ath-
erosclerotic disease. This is physiologically plausible in
chronic infection; however low HDL at hospital admis-
sion could also simply reﬂect similarly low levels of TC/
LDL and may not be indicative of increased long-term
CVD risk. That uncertainty can only be resolved by well-
powered studies with adequate follow-up, to provide suf-
ﬁcient evidence to address current gaps in evidence
and, ultimately, guide clinical practice. Nevertheless, if
proven, targeted prevention programmes that identify
and actively manage individuals with a history of CD
(particularly an active case) and with low levels of
HDLC may be indicated. The alternative is an increasing
burden of non-communicable forms of HD in urban
African communities that is supplemented (in origin
and conﬂuence) by historical cases of communicable
disease that have adversely affected protective HDLC
levels (particularly in women).
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